Ten children with hematologic malignancies or a storage disease underwent transplantation using cord blood cells from an unrelated donor mismatched for 1 (n ‫؍‬ 7) or 2 (n ‫؍‬ 3) HLA antigens. The median total nucleated cell dose was 4.0 (range, 2.2-7.1) ؋ 10 7 /kg. GVHD prophylaxis consisted of tacrolimus doseadjusted to maintain a whole blood level of 5-15 ng/ml with or without methotrexate 5 mg/m 2 i.v. on days 1, 3, 6 and 11. Corticosteroids were not administered prophylactically. Median follow-up is 12 months (range, 5-28 months). One patient had autologous recovery and subsequently relapsed 153 days post transplant. For the remainder of the patients, the median time to an ANC Ͼ0.5 ؋ 10 9 /l was 21 days (range, 19-38 days), and the median time to platelets Ͼ20 ؋ 10 9 /l was 39 days (range, 21-97 days). The actuarial risk of grade 2 GVHD was 77% (95% CI, 49-100%), and no patient had grades 3-4 GVHD. Two patients developed chronic GVHD. The survival rate is 90% (95% CI, 81-100%). The combination of tacrolimus and minidose methotrexate is active for the prevention of severe but not moderate acute GVHD after mismatched unrelated donor cord blood transplantation. Keywords: cord blood transplantation; graft-versus-host disease prophylaxis; tacrolimus; unrelated donor Indications for allogeneic transplantation in the pediatric population have increased greatly over the past decade, and now include metabolic storage diseases and hemoglobinopathies in addition to immunodeficiency disorders, marrow failure states and hematologic malignancies. The pool of potential donors has also recently expanded with the introduction of unrelated donor cord blood transplantation (CBT).
Indications for allogeneic transplantation in the pediatric population have increased greatly over the past decade, and now include metabolic storage diseases and hemoglobinopathies in addition to immunodeficiency disorders, marrow failure states and hematologic malignancies. The pool of potential donors has also recently expanded with the introduction of unrelated donor cord blood transplantation (CBT). [1] [2] [3] [4] [5] An unexpected advantage of CBT was the lower risk of acute graft-versus-host disease (GVHD) in comparison to marrow or mobilized peripheral blood stem cell transplantation. 6 This is thought to result from the relative immaturity of the T cells in cord blood. and cytokine profile, do not express IL-2 receptors, and have a V␤ chain diversity consistent with lack of prior antigenic stimulation. 7, 8 However, the incidence of acute GVHD with CBT from HLA-mismatched unrelated donors remained substantial (38-73%), and the associated treatment-related mortality has limited long-term outcome. [1] [2] [3] [4] [5] [6] Tacrolimus is an immunosuppressive macrolide lactone that inhibits the effects of calcineurin in the earliest steps of T cell activation, a mechanism of action similar to that of cyclosporine, but the potency of tacrolimus in vitro is more than 100 times that of cyclosporine. 9 This suggested that tacrolimus might be more effective than cyclosporine as GVHD prophylaxis in high-risk settings. We 10,11 and others 12, 13 have reported that the combination of tacrolimus and methotrexate (MTX) is active in preventing acute GVHD after alternative donor marrow transplantation (unrelated donor marrow or mismatched related donor marrow transplantation) in adults, and the superiority of tacrolimus over cyclosporine as GVHD prophylaxis was recently demonstrated in a randomized study of unrelated donor marrow transplant recipients.
14 Here, we describe our experience with tacrolimus for prevention of GVHD after mismatched unrelated donor cord blood transplantation, another type of alternative donor transplant.
Patients and methods

Patients
From March 1996 to April 1998, 10 children underwent unrelated donor cord blood transplantation at the MD Anderson Cancer Center using tacrolimus-based GVHD prophylaxis. Treatment was approved by the Institutional Review Board, and written informed consent was obtained from the guardian of each patient. The group was comprised of seven males and three females of median age 6 years (range, 9 months to 15 years) ( Table 1) . Eight patients had leukemia, one had intermediate grade malignant lymphoma, and one had Hunter's syndrome. The lymphoma patient had previously failed autologous transplantation.
Cord blood transplants
Patient HLA typing was performed by standard serologic techniques, and polymerase chain reaction with sequence specific primers was used to subtype HLA-DR. 15 Cord blood units were obtained from commercial cord blood M ϭ male; F ϭ female; ANL ϭ acute nonlymphoblastic leukemia; ALL ϭ acute lymphoblastic leukemia; MDS ϭ myelodysplastic syndrome; NHL ϭ non-Hodgkin's lymphoma; Rem ϭ remission; Rel ϭ relapse; TBI ϭ total body irradiation; FLU ϭ fludarabine; MEL ϭ melphalan; THIO ϭ thiotepa; BU ϭ busulfan; CYC ϭ cyclophosphamide; ATG ϭ antithymocyte globulin; MTX ϭ methotrexate; DAH ϭ diffuse alveolar hemorrhage. banks; class I typing performed by the bank was accepted, and confirmatory molecular typing for class II was performed whenever samples were available. Classification of major MHC disparity was based on serologic typing for HLA-A and -B, and low resolution typing for HLA-DR. Two patients with a major mismatch in class I also had a molecular mismatch on high resolution typing for HLA-DR␤1. None of the patients with two major class I mismatches had a molecular mismatch at HLA-DR␤1. Cord blood units were shipped on liquid nitrogen and stored until use. On day 0, the unit was thawed and infused without further processing. The total nucleated cell count and CD34 ϩ cell dose reported (Table 2 ) were recorded at the time of cryopreservation and provided by the cord blood bank.
Preparative regimens and supportive care
The myeloablative regimens consisted of TBI 8.5-9.0 Gy day Ϫ7, fludarabine 30 mg/m 2 i.v. days Ϫ6 to Ϫ2, and melphalan 140 mg/m 2 i.v. day Ϫ1 (TFM); thiotepa 250 mg/m 2 i.v. days Ϫ9 to Ϫ7, busulfan 40 mg/m 2 orally every 6 h days Ϫ6 to Ϫ4 with dose adjustments according to pharmacokinetics, 16 and cyclophosphamide 60 mg/kg i.v. days Ϫ3 and Ϫ2 (TBC); or busulfan 40 mg/m 2 orally every 6 h days Ϫ7 to Ϫ4, cyclophosphamide 60 mg/kg i.v. days Ϫ3 and Ϫ2, and ATG 30 mg/kg i.v. days Ϫ3 to Ϫ1 (BuCyc). Day 0 is the day of transplantation. All patients received filgrastim 5 g/kg s.c. post transplant through engraftment. The details of other standard supportive care, including nursing care, prophylactic antibiotics and transfusion support, have been published. 10 
GVHD prophylaxis and monitoring
Methotrexate (MTX) was administered according to the policy at the time of transplantation. One child received no MTX, and the remainder were to receive minidose MTX (MTX 5 mg/m 2 i.v. on days 1, 3, 6 and 11). Tacrolimus was administered at 0.03 mg/kg/day i.v. by continuous infusion from day Ϫ2. Following engraftment when the patient was able to take medications orally, the 24-h dose of tacrolimus was converted 1 i.v. : 4 p.o., given orally (1 mg dose form or as the liquid preparation at 0.5 mg/ml in Simple Syrup USP) in a twice-daily divided dose to at least day 180 and tapered thereafter. Doses were adjusted to maintain whole blood steady state or trough levels at 5-15 ng/ml. Tacrolimus was discontinued or reduced in dose when blood levels were elevated or the serum creatinine was increased. Corticosteroids were not administered as part of GVHD prophylaxis. Patients were observed prospectively for development of acute GVHD. The diagnosis of GVHD was based on clinical evidence with histologic confirmation. Acute GVHD was graded by one of the investigators (K-WC) according to the consensus criteria, 17 and chronic GVHD was diagnosed and graded according to the Seattle criteria. 18 
Definitions and statistical considerations
Neutrophil recovery was defined as the first of 3 consecutive days that the absolute neutrophil count (ANC) exceeded the target number (0.5 or 1.0 ϫ 10 9 /l), and platelet recovery was defined as the day that the platelet count exceeded the target number (20 or 50 ϫ 10 9 /l) with no platelet transfusions the following week. Hematopoietic chimerism was evaluated by restriction fragment length polymorphisms. At the time of analysis, median time from transplantation was 12 months (range, 5-28 months). Actuarial estimates of acute GVHD, chronic GVHD and survival were calculated according to the method of Kaplan and Meier. 19 
Results
Engraftment
The median time for platelet recovery was 39 (range, 21-97) days to platelets Ͼ20 ϫ 10 9 /l and 54 (range, 30-122) days to platelets Ͼ50 ϫ 10 9 /l ( Table 2) . One patient expired before platelet recovery. Nine of the 10 patients had recovery of neutrophils with documentation of donor hematopoiesis. The median time to neutrophil recovery was 21 (range, 19-38) days to an ANC Ͼ0.5 ϫ 10 9 /l and 24 (range, 19-39) days to ANC Ͼ1.0 ϫ 10 9 /l. There was no correlation between total nucleated cell dose and time to neutrophil or platelet recovery. One patient (Table 2, patient No. 5) had an ANC Ͼ0.5 ϫ 10 9 /l by day 45, but hematopoiesis was recipient in origin by chimerism studies. This patient relapsed on day 153. He was treated with TFM and received a 2-antigen mismatched unrelated donor cord blood transplant. Neutrophil recovery occurred on day 21 after the second transplantation, and full donor chimerism was detected.
Toxicity
Three of nine patients missed one dose of MTX because of toxicity. All patients required modification of the tacrolimus dose, but tacrolimus-related toxicity was mild. Seven of 10 patients had a doubling of serum creatinine from baseline, two had a peak serum creatinine exceeding 1 mg/dl (none exceeded 2 mg/dl), and none were dialyzed. Following discharge to the outpatient setting, one patient was treated for hypertension, and none required insulin for persistent hyperglycemia.
Graft-versus-host disease
Seven patients developed grade 2 GVHD, and none had grades 3-4 GVHD ( Table 2 ). Isolated skin GVHD was seen most commonly. No patient received more than high-dose steroids for treatment of acute GVHD. The actuarial risk was 77% (95% CI, 49-100%) for grades 2-4 GVHD and 22% (95% CI, 0-48) for chronic GVHD. Chronic GVHD was limited to the skin and responded rapidly to a short course of corticosteroids.
Relapse and survival
One patient relapsed, and he is alive in remission 3 months after the second cord blood transplantation. At 8 months post transplant, the patient with Hunter's syndrome had a serum iduronate-2-sulfatase level 22% of control (vs 0.5% pretransplant) and normal urinary glycosaminoglycans. One patient expired day 104 with diffuse alveolar hemorrhage; the patient had been treated successfully for acute GVHD (Table 2) . With a median follow-up of 12 months (range, 5-28 months), the actuarial survival is 90% (95% CI, 81-100%) (Figure 1 ).
Discussion
Use of tacrolimus for prevention of acute GVHD has been evaluated extensively in the adult marrow transplant population, but its activity in pediatric patients is unknown. Our institutional experience demonstrated that the dose-schedule used in the adults was appropriate for pediatric patients as well. 20 Using this dose-schedule, we found that tacrolimus-based immunosuppression was very active for prevention of severe acute GVHD in mismatched unrelated donor CBT in the pediatric patients, and no patient developed steroid-refractory acute GVHD. The incidence of moderate acute GVHD (77%) in our patients was similar to that reported using cyclosporine-based regimens, [1] [2] [3] [4] [5] [6] but definitive statements regarding the comparability of tacrolimus and cyclosporine for unrelated donor CBT will require a randomized study.
We reported previously that when used in combination with tacrolimus, the dose of MTX can be reduced without impairing the clinical potency of the immunoprophylaxis. 10 For the CBT patients in this study, whether three or four doses of MTX were administered did not appear to affect the risk of GVHD, although the number of patients is quite small. It is noteworthy, however, that our results were achieved without the use of prophylactic corticosteroids or antithymocyte globulin. The effect of a pulse of high-dose methylprednisolone in the early post-transplant period on survival in CBT recipients has been inconsistent. 1, 21, 22 Whether a steroid pulse would improve control of moderate GVHD after CBT when using tacrolimus without increasing the infection rate remains to be determined.
A correlation between total nucleated cell dose and hematopoietic recovery after CBT has been reported by several groups, and use of hematopoietic growth factors, thawing technique, HLA disparity and diagnosis have also been shown to affect neutrophil recovery. 1, 3, 5, 21 We found no correlation between nucleated cell dose and neutrophil or platelet recovery in our small number of patients. MTX was used infrequently in other series. Our experience showed that minidose MTX did not appear to delay recovery; the range of times to return of neutrophils in our patients (19-38 days) is consistent with the literature. Platelet recovery was delayed, and this may also have been affected by the high rate of GVHD in our patients or by the low number of stem cells as is typical of a cord blood transplant. In the absence of published experience with tacrolimus and CBT, we were also concerned about the potential for graft failure due to tacrolimus, a concern allayed by the report of Hirao et al 23 that tacrolimus stimulated hematopoiesis from cord blood cells in vitro. In our series, only one patient failed to engraft, and this may have been due to impending leukemia relapse.
Over 650 patients have undergone unrelated donor CBT, and this modality now rivals use of unrelated donor BMT for pediatric patients who do not have an HLA-matched related donor. One major advantage of CBT over BMT is the lower risk of acute GVHD. With HLA-mismatched unrelated donor BMT in children, the incidence of grades 3-4 GVHD has been 30-62%. 24, 25 The risk of GVHD could be reduced by T cell depletion, 26, 27 but in either case, treatment-related mortality was high and exceeded 50% in some reports. 24 A striking feature of our series is the relatively low early mortality (0% at 100 days post transplant) and 90% survival at 6 months post transplant. We reported previously a reduction in early mortality after HLA-identical BMT or SCT with tacrolimus in comparison to cyclosporine for adult patients with advanced leukemia. 28 The reduction in severe acute GVHD achieved with the use of tacrolimus may account for the decrease in early mortality in our patients. These results suggest that further evaluation of tacrolimus in pediatric patients at high risk for GVHD is warranted.
